Concert Pharmaceuticals, Inc. CNCE
We take great care to ensure that the data presented and summarized in this overview for CONCERT PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNCE
View allLatest Institutional Activity in CNCE
Top Purchases
Top Sells
About CNCE
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Insider Transactions at CNCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2023
|
Wilfred E Jaeger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,400
-100.0%
|
-
|
|
Mar 06
2023
|
Wilfred E Jaeger Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,125
-100.0%
|
-
|
|
Mar 06
2023
|
Jeffrey A Munsie Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,699
-100.0%
|
-
|
|
Mar 06
2023
|
Jeffrey A Munsie Chief Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
38,350
-100.0%
|
-
|
|
Mar 06
2023
|
Nancy Stuart Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
73,233
-100.0%
|
-
|
|
Mar 06
2023
|
Nancy Stuart Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
167,963
-100.0%
|
-
|
|
Mar 06
2023
|
Roger D Tung Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
147,536
-100.0%
|
-
|
|
Mar 06
2023
|
Roger D Tung Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,916
-100.0%
|
-
|
|
Mar 06
2023
|
Roger D Tung Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
756,427
-100.0%
|
-
|
|
Mar 06
2023
|
Christi Van Heek Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,400
-100.0%
|
-
|
|
Mar 06
2023
|
Christi Van Heek Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,651
-100.0%
|
-
|
|
Mar 06
2023
|
Thomas G Auchincloss Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,400
-100.0%
|
-
|
|
Mar 06
2023
|
Thomas G Auchincloss Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,625
-100.0%
|
-
|
|
Mar 06
2023
|
Marc A. Becker Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
49,699
-100.0%
|
-
|
|
Mar 06
2023
|
Marc A. Becker Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,264
-100.0%
|
-
|
|
Mar 06
2023
|
James V Cassella Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,766
-100.0%
|
-
|
|
Mar 06
2023
|
James V Cassella Chief Development Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
80,595
-100.0%
|
-
|
|
Mar 06
2023
|
Jesper Hoeiland Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,400
-100.0%
|
-
|
|
Mar 06
2023
|
Jesper Hoeiland Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,125
-100.0%
|
-
|
|
Mar 06
2023
|
Peter Barton Hutt Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,400
-100.0%
|
-
|